Aardvark Therapeutics, Inc. (AARD) FinancialsAARDAardvark Therapeutics, Inc.

Evaluating the bottom line, Aardvark Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -66.02%, provide a clear picture of how effectively AARD converts its operational activities into shareholder value.

In the context of the broader market, AARD competes directly with industry leaders such as CRBP and CPIX. With a market capitalization of $84.48M, it holds a significant position in the sector. When comparing efficiency, AARD's gross margin of N/A stands against CRBP's N/A and CPIX's 100.00%. Such benchmarking helps identify whether Aardvark Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Aardvark has reported consistent net losses, with a net income of -$14.4 million in Q2 2026, reflecting ongoing financial struggles. The EPS for Q2 2026 was -0.66, unchanged from the previous year, indicating persistent financial pressure.